Chardan took over coverage of uniQure (QURE) with a Buy rating and price target of $38. The analyst, who cites the potential of the company’s ...

让我们先来看一个真实的案例。一位47岁的女性患者，主诉蛋白尿20余年，最终被诊断为法布雷病合并慢性肾脏病。她曾接受过多次手术，包括卵巢囊肿术、畸胎瘤术、心肌肥厚切除术和永久性双腔起搏器植入术。她的病情复杂，涉及多个器官系统，包括肾脏、心脏、皮肤等。

法布雷病（Fabry disease，FD），一种罕见的遗传性溶酶体贮积病，因GLA基因突变导致其编码的α-半乳糖苷酶A活性降低，进而导致三己糖酰基鞘脂醇（GL-3）及其衍生物在多个器官内贮积，造成患者健康严重损害。这种病在全世界的发病率约为1/100000，是一种可致命的疾病，尤其是肾脏、心脏和神经系统的损伤严重影响了患者的生活质量。更令人痛心的是，法布雷病已被列入中国首批罕见病目录，而因其罕见 ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 20.19%, which has investors questioning if this is right time to buy.

The following is a summary of “Cutaneous manifestations of Fabry disease: A systematic review,” published in the March 2025 ...

Looking for things to do with your kids? Check out the full March calendar at wncparent.com, and be sure to take a look at ...

The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)tm Study ? the first national CKD patient registry that captures both ...

The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)™ Study – ...

Protalix Biotherapeutics (PLX) has gained investor’s attention, and reported a record revenue increase in its fiscal year 2024, primarily due ...

In the assessment of 12-month price targets, analysts unveil insights for Sangamo Therapeutics, presenting an average target of $6.5, a high estimate of $10.00, and a low estimate of $2.00.

Q4 2024 Earnings Call Transcript March 17, 2025 Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Sangamo Therapeutics Inc (SGMO) reports significant progress in its Fabry disease program and neurology therapies, while navigating financial hurdles and partnership negotiations.